Education
About Us
Working with TipRanks
Follow Us
Valbiotis SA (FR:ALVAL)
:ALVAL
ALVAL Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.94 - €4.00
Previous CloseN/A
Volume46.53K
Average Volume (3M)53.97K
Market Cap
€18.44M
Enterprise ValueN/A
Total Cash (Recent Filing)€25.02M
Total Debt (Recent Filing)€6.88M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Sep 25, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.64
Shares Outstanding15,910,365
10 Day Avg. Volume59,357
30 Day Avg. Volume53,974
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.29
Price to Sales (P/S)0.00
P/FCF Ratio-10.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Valbiotis SA News
PremiumCompany Announcements
Valbiotis Announces Monthly Voting Rights and Share Capital Update
PremiumCompany Announcements
Valbiotis Introduces Lipidrive as a Safe Alternative to Red Yeast Rice
PremiumCompany Announcements
Valbiotis SA Confirms Strategic Growth and Successful Product LaunchPremiumCompany Announcements
Valbiotis Releases Monthly Voting Rights and Share Capital Data
PremiumCompany Announcements
Valbiotis Releases Monthly Voting Rights and Shares Update
PremiumCompany Announcements
Valbiotis Launches Innovative Metabolic Health Supplement in France
ALVAL FAQ
What was Valbiotis SA’s price range in the past 12 months?
Valbiotis SA lowest stock price was €0.94 and its highest was €4.00 in the past 12 months.
What is Valbiotis SA’s market cap?
Valbiotis SA’s market cap is €18.44M.
When is Valbiotis SA’s upcoming earnings report date?
Valbiotis SA’s upcoming earnings report date is Sep 25, 2025 which is in 116 days.
How were Valbiotis SA’s earnings last quarter?
Valbiotis SA released its earnings results on Mar 03, 2025. The company reported -€0.414 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.414.
Is Valbiotis SA overvalued?
According to Wall Street analysts Valbiotis SA’s price is currently Overvalued.
Does Valbiotis SA pay dividends?
Valbiotis SA does not currently pay dividends.
What is Valbiotis SA’s EPS estimate?
Valbiotis SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Valbiotis SA have?
Valbiotis SA has 15,910,365 shares outstanding.
What happened to Valbiotis SA’s price movement after its last earnings report?
Valbiotis SA reported an EPS of -€0.414 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.156%.
Which hedge fund is a major shareholder of Valbiotis SA?
Currently, no hedge funds are holding shares in FR:ALVAL
Company Description
Valbiotis SA
Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.